Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 4
Tirzepatide Before an Endocrine Crisis
A case linked first-dose tirzepatide timing with a probable pheochromocytoma crisis, but tumor confirmation and drug causality remained unresolved.
Can Wegovy Affect an Alcohol Interlock?
A single Wegovy case report proposes a ketone-to-isopropanol route for disputed alcohol interlock results, but lacks chemical confirmation.
Calcitonin During Tirzepatide Therapy
A 76-person observational study found a small early calcitonin rise during tirzepatide therapy, but only two threshold events limited prediction.
GLP-1 review maps field without new data
A new GLP-1 review explains physiology and drug development but enrolls no participants and reports no original outcomes.
GLP-1 Review Maps PAD Evidence
A 2026 clinical review reports no new trial, while mapping semaglutide walking data and the weaker evidence on major limb events.
GLP1R Variants and Weight Loss Response
Rare GLP1R variants were linked to less weight loss with semaglutide, while a small tirzepatide carrier group had a near-normal response.
SOUL recurrent events: oral semaglutide
A secondary SOUL analysis counted first and later cardiovascular events. We separate its total-event result from the parent trial's primary endpoint.
Semaglutide in Youths With Autism
A retrospective cohort linked semaglutide with greater weight reductions in youths with autism and obesity, but only 20 received treatment.
Tirzepatide, Saliva and Complete Dentures
A 2026 letter raises a denture-saliva question but reports no participants, salivary measures, or clinical denture outcomes.
Resistance Exercise With Tirzepatide
A 40-week randomized trial found that supervised resistance exercise reduced lean soft tissue loss and improved strength during tirzepatide treatment.
Tirzepatide Weight Response in Practice
A retrospective cohort found different tirzepatide weight trajectories by diabetes status, but prior GLP-1 treatment complicated the comparison.
Trevogrumab Preserved Lean Mass in COURAGE
A phase 2 trial found less lean-mass loss with trevogrumab during semaglutide treatment, while the garetosmab combination raised safety concerns.